Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N5R0 | ISIN: US9842411095 | Ticker-Symbol:
NASDAQ
25.06.25 | 21:58
4,920 US-Dollar
0,00 % 0,000
1-Jahres-Chart
Y-MABS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
Y-MABS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur Y-MABS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.Clear Street erhöht Kursziel für YMAB-Aktie auf 17 US-Dollar, Aktien steigen1
28.05.Clear Street raises YMAB stock target to $17, shares rise1
28.05.Y-mAbs Therapeutics, Inc. - 8-K, Current Report1
28.05.Y-mAbs Therapeutics, Inc.: Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline3
26.05.Y-mAbs Therapeutics, Inc.: Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting2
Y-MABS THERAPEUTICS Aktie jetzt für 0€ handeln
19.05.What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics1
19.05.H.C. Wainwright cuts YMAB stock target to $11, maintains Buy rating1
13.05.Y-mAbs Therapeutics outlines Q2 revenue guidance of $17M-$19M amid DANYELZA NCCN guideline inclusion and expanded ex-U.S. growth1
13.05.Y-mAbs Therapeutics, Inc. - 10-Q, Quarterly Report-
13.05.Y-mAbs Therapeutics, Inc. - 8-K, Current Report1
13.05.Y-mAbs Therapeutics, Inc.: Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 20251
13.05.Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook3
13.05.Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments256Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines...
► Artikel lesen
12.05.Preview: Y-mAbs Therapeutics' Earnings1
07.05.Y-mAbs gets NCCN recommendation for neuroblastoma treatment2
07.05.Y-mAbs Therapeutics, Inc.: Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA)135PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
► Artikel lesen
06.05.Y-mAbs Therapeutics, Inc.: Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 20252
27.04.Y-mAbs Therapeutics, Inc.: Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting119NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization...
► Artikel lesen
25.04.Y-mAbs beginnt Studie für neue Non-Hodgkin-Lymphom-Behandlung1
25.04.Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment1
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1